title: Reply to "A strong message is needed to address the issue of HCC recurrence after DAA therapy".
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMRS 1136, F75012 Paris, France; AP-HP, Hôpital Saint Antoine, Unité de Santé Publique, France.
authors.forename: F
authors.initials: F
authors.lastname: Carrat
authors.affiliation: AP-HP, Hôpital Jean Verdier, Service d'Hépatologie, Bondy;Université Paris 13, Sorbonne Paris Cité, "Equipe labellisée Ligue Contre le Cancer", F-93206 Saint-Denis, France Inserm, UMR-1162, "Génomique fonctionnelle des tumeur solides", F-75000 Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Nahon
authors.affiliation: AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, and Université Paris-Sud, and Université Paris-Saclay, UMR-S 1193, and INSERM Unité 1193, and DHU Hepatinov, Villejuif, France.
authors.forename: J C
authors.initials: JC
authors.lastname: Duclos-Vallée
authors.affiliation: CHU Saint-Eloi, Département d'hépato-gastroentérologie et de transplantation hépatique, and Université de Montpellier, Montpellier, France.
authors.forename: G P
authors.initials: GP
authors.lastname: Pageaux
authors.affiliation: Université Paris Descartes; APHP, Unité d'Hépatologie, Hôpital Cochin; INSERM U-1016, Institut Cochin, Paris, France.
authors.forename: H
authors.initials: H
authors.lastname: Fontaine
authors.affiliation: Université Paris Descartes; APHP, Unité d'Hépatologie, Hôpital Cochin; INSERM U-1016, Institut Cochin, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Pol
mesh_terms: D000998:Antiviral Agents; D006528:Carcinoma, Hepatocellular; D006801:Humans; D008113:Liver Neoplasms; D009364:Neoplasm Recurrence, Local
chemical_list: D000998:Antiviral Agents